Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Lawson, S. Wolf (2009)ICAM-1 signaling in endothelial cells
Pharmacological Reports, 61
P. Libby, Y. Okamoto, V. Rocha, E. Folco (2010)Inflammation in atherosclerosis: transition from theory to practice.
Circulation journal : official journal of the Japanese Circulation Society, 74 2
C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, W. Koenig (2005)Plasma Oxidized Low-Density Lipoprotein, a Strong Predictor for Acute Coronary Heart Disease Events in Apparently Healthy, Middle-Aged Men From the General Population
Michael Davidson, C. Ballantyne, T. Jacobson, V. Bittner, L. Braun, Alan Brown, W. Brown, W. Cromwell, R. Goldberg, J. Mckenney, A. Remaley, A. Sniderman, P. Toth, S. Tsimikas, P. Ziajka, K. Maki, M. Dicklin (2011)Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
Journal of clinical lipidology, 5 5
C. Ballantyne, R. Hoogeveen, H. Bang, J. Coresh, A. Folsom, L. Chambless, M. Myerson, K. Wu, A. Sharrett, E. Boerwinkle (2005)Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Archives of internal medicine, 165 21
H. Bays (2007)Safety considerations with omega-3 fatty acid therapy.
The American journal of cardiology, 99 6A
CM Ballantyne, HE Bays, JJ Kastelein (2012)A phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study to evaluate the effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (≥200 and <500 mg/dL): the ANCHOR study
Am J Cardiol, 110
P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto, J. Kastelein, W. Koenig, P. Libby, A. Lorenzatti, Jean Macfadyen, B. Nordestgaard, J. Shepherd, J. Willerson, R. Glynn (2008)Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine, 359 21
(Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79–81.)Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79–81.
Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79–81., Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79–81.
C. Ballantyne, H. Bays, J. Kastelein, E. Stein, J. Isaacsohn, R. Braeckman, Paresh Soni (2012)Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
The American journal of cardiology, 110 7
C. Ballantyne, R. Hoogeveen, H. Bang, J. Coresh, A. Folsom, G. Heiss, A. Sharrett (2004)Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
Circulation: Journal of the American Heart Association, 109
M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, K. Shirato (2007)Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
The Lancet, 369
H. Schuett, M. Luchtefeld, C. Grothusen, K. Grote, B. Schieffer (2009)How much is too much? Interleukin-6 and its signalling in atherosclerosis
Thrombosis and Haemostasis, 102
Ann Skulas-Ray, P. Kris-Etherton, W. Harris, J. Heuvel, P. Wagner, S. West (2011)Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.
The American journal of clinical nutrition, 93 2
M. Corson, Peter Jones, M. Davidson (2008)Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
The American journal of cardiology, 101 12A
H. Bays (2008)Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
Drugs of today, 44 3
M. Mesa, R. Buckley, A. Minihane, P. Yaqoob (2004)Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein.
Atherosclerosis, 175 2
Dr Ballantyne has received research grants from Abbott Laboratories , Amarin Pharma, Inc., AstraZeneca, Bristol-Myers Squibb, diaDexus, GlaxoSmithKline, Kowa Pharmaceuticals America, Inc., Merck & Co
D. Chan, G. Watts, P. Barrett, L. Beilin, T. Mori (2002)Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
Clinical chemistry, 48 6 Pt 1
Shih-Jen Hwang, C. Ballantyne, A. Sharrett, L. Smith, C. Davis, A. Gotto, E. Boerwinkle (1997)Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.
Circulation, 96 12
H. Bays, A. Tighe, R. Sadovsky, M. Davidson (2008)Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications
Expert Review of Cardiovascular Therapy, 6
H. Itakura, M. Yokoyama, M. Matsuzaki, Y. Saito, H. Origasa, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, K. Shirato, Y. Matsuzawa (2011)Relationships between plasma fatty acid composition and coronary artery disease.
Journal of atherosclerosis and thrombosis, 18 2
17], this analysis showed that IPE 4 g/day significantly decreased Ox-LDL, Lp-PLA 2 , and hsCRP levels and thus may offer a combination of beneficial lipid and anti-inflammatory effects
C. Ballantyne, R. Hoogeveen, H. Bang, J. Coresh, A. Folsom, G. Heiss, A. Sharrett (2004)Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study
M. Micallef, Irene Munro, Manohar Garg (2009)SHORT COMMUNICATION An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals
C. Glass, J. Witztum (2001)Atherosclerosis The Road Ahead
N Satoh, A Shimatsu, K Kotani (2007)Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome
Diabetes Care, 30
E. Watanabe, Y. Sobue, Kan Sano, K. Okuda, Mayumi Yamamoto, Y. Ozaki (2011)Eicosapentaenoic Acid for the Prevention of Recurrent Atrial Fibrillation
Annals of Noninvasive Electrocardiology, 16
Maria Pedersen, W. Koenig, J. Christensen, E. Schmidt (2009)The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults
European Journal of Nutrition, 48
L. Garrido-Sánchez, E. García‐Fuentes, G. Rojo-Martínez, F. Cardona, F. Soriguer, F. Tinahones (2008)Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA)
British Journal of Nutrition, 100
P. Toth, P. McCullough, M. Wegner, Kenneth Colley (2010)Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker
Expert Review of Cardiovascular Therapy, 8
N. Satoh, A. Shimatsu, K. Kotani, A. Himeno, T. Majima, Kazunori Yamada, T. Suganami, Yoshihiro Ogawa (2009)Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome
Hypertension Research, 32
(2011)Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females
D. Kelley, D. Siegel, D. Fedor, Y. Adkins, B. Mackey (2009)DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men.
The Journal of nutrition, 139 3
R. Bloomer, D. Larson, Kelsey Fisher-Wellman, A. Galpin, B. Schilling (2009)Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study
Lipids in Health and Disease, 8
with funding from Amarin Pharma Inc. Editorial assistance was provided by Peloton Advantage
Trevor Mori, R. Woodman, V. Burke, I. Puddey, K. Croft, L. Beilin (2003)Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects.
Free radical biology & medicine, 35 7
(2010)Fish oils in the treatment of dyslipidemia and cardiovascular disease
The Johns Hopkins textbook of dyslipidemia
I. Levitan, S. Volkov, P. Subbaiah (2010)Oxidized LDL: diversity, patterns of recognition, and pathophysiology.
Antioxidants & redox signaling, 13 1
P. Kwiterovich (2010)The Johns Hopkins textbook of dyslipidemia
H. Bays (2011)Adiposopathy is "sick fat" a cardiovascular disease?
Journal of the American College of Cardiology, 57 25
P. Ridker, N. Rifai, M. Clearfield, J. Downs, S. Weis, J. Miles, A. Gotto (2001)Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
The New England journal of medicine, 344 26
MA Micallef, IA Munro, ML Garg (2009)An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals
Eur J Clin Nutr, 63
H. Bays, C. Ballantyne, J. Kastelein, J. Isaacsohn, R. Braeckman, Paresh Soni (2011)Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
The American journal of cardiology, 108 5
M. Davidson, K. Maki, H. Bays, Roderick Carter, C. Ballantyne (2009)Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
Journal of clinical lipidology, 3 5
T. Nyström (2007)C-reactive protein: a marker or a player?
Clinical science, 113 2
Am J Cardiovasc Drugs (2013) 13:37–46 DOI 10.1007/s40256-012-0002-3 OR IGINAL RESEARCH ARTIC L E Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inﬂammation from the MARINE and ANCHOR Studies • • Harold E. Bays Christie M. Ballantyne • • Rene A. Braeckman William G. Stirtan Paresh N. Soni Published online: 17 January 2013 The Author(s) 2013. This article is published with open access at Springerlink.com Abstract oxidized low-density lipoprotein (Ox-LDL), lipoprotein- Background Icosapent ethyl (IPE) is a high-purity associated phospholipase A (Lp-PLA ), interleukin-6 2 2 prescription form of eicosapentaenoic acid ethyl ester (IL-6), and high-sensitivity C-reactive protein (hsCRP). approved by the US Food and Drug Administration as an Results Compared to placebo, IPE 4 g/day signiﬁcantly adjunct to diet to reduce triglyceride (TG) levels in adult decreased Ox-LDL (13 %, p \ 0.0001, ANCHOR), patients with severe (C500 mg/dL) hypertriglyceridemia. Lp-PLA (14 %, p \ 0.001, MARINE; 19 %, p \ 0.0001, In addition to TG-lowering effects, IPE also reduces non- ANCHOR), and hsCRP levels (36 %, p \ 0.01, MARINE; high-density lipoprotein cholesterol and apolipoprotein B 22 %, p \ 0.001, ANCHOR), but did not signiﬁcantly levels without signiﬁcantly increasing low-density
American Journal of Cardiovascular Drugs – Springer Journals
Published: Jan 17, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.